ITVISMA APPROVAL
US Stocks: Biogen gets FDA approval for higher dose of genetic disorder drug, shares rise 3%The U.S. Food and Drug Administration has approved a higher dose of Biogen's spinal muscular atrophy drug Spinraza, the company said on M...
US FDA approves Novartis' gene therapy for rare muscle disorderThe US FDA has approved Novartis' new gene therapy, Itvisma, which is for patients aged two and above with spinal muscular atrophy. Itvisma...
- Load More